Gain Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Gain Therapeutics generated cash of -$18,865,873, which is less than the previous year. Cash used in financing activities reached the amount of $12,641,343 last year. Net change in cash is therefore $4,486,541.
Cash Flow
| 2018 | -744.51K | -7.98K | 983.77K |
|---|---|---|---|
| 2019 | -1.86M | -13.72K | 1.75M |
| 2020 | -3.24M | -20.82K | 10.48M |
| 2021 | -12.36M | -94.21K | 41.76M |
| 2022 | -14.69M | -14.77M | -78.77K |
| 2023 | -18.86M | 10.22M | 12.64M |
GANX Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 7.34M | 36.91M | 7.50M | 313.7K | 410.88K | 173.00K |
Operating activities | ||||||
Net income | -22.26M | -17.59M | -13.89M | -3.57M | -2.19M | -1.10M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 83.57K | 64.16K | 15.48K | 9.59K | 2.57K | 741 |
Stock-based compensation expense | 3.25M | 1.52M | 839.37K | 81.64K | 0 | 0 |
| Deferred income tax benefit | 3.25M | 1.52M | 839.37K | 81.64K | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 8.26K | -196 | -8.35K | 0 |
Inventories | 0 | 0 | 93.31K | -28.52K | 96.51K | 0 |
Accounts payable | -643.16K | 1.06M | -521.39K | 395.54K | 5.10K | 117.68K |
Cash generated by operating activities | -18.86M | -14.69M | -12.36M | -3.24M | -1.86M | -744.51K |
Investing activities | ||||||
Purchases Of Investments | -1.95M | -17.73M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -15.35K | -118.95K | -94.21K | -20.82K | -13.72K | -7.98K |
Acquisitions Net | 0 | 14.65M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 10.22M | -14.77M | -94.21K | -20.82K | -13.72K | -7.98K |
Financing activities | ||||||
Common Stock Issued | 12.73M | 0 | 42.64M | 177 | 1.75M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -89.06K | -78.77K | -21.95K | -738.28K | 0 | 0 |
Cash used in financing activities | 12.64M | -78.77K | 41.76M | 10.48M | 1.75M | 983.77K |
Net Change In Cash | 4.48M | -29.56M | 29.40M | 7.19M | -97.18K | 237.88K |
Cash at end of period | 11.82M | 7.34M | 36.91M | 7.50M | 313.7K | 410.88K |
| Data source | Data source | Data source |